Login / Signup

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.

Ting XuJian LiZhenghang WangXiaotian ZhangJun ZhouZhihao LuLin ShenXicheng Wang
Published in: Cancer medicine (2023)
BRAF V600E mutant mCRCs exhibit unfavorable and heterogeneous prognosis. The first-line intensive chemotherapy did not confer a marked impact on the PFS and OS.
Keyphrases
  • wild type
  • metastatic colorectal cancer
  • locally advanced
  • type diabetes
  • skeletal muscle
  • combination therapy
  • insulin resistance
  • replacement therapy
  • chemotherapy induced